Welcome to our dedicated page for GENWORTH FINANCIAL SEC filings (Ticker: GNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genworth Financial, Inc. filings document formal earnings disclosures for an insurance holding company with Enact mortgage insurance operations and a Closed Block of long-term care insurance, life insurance and annuity products. Recent Form 8-K reports furnish quarterly results press releases and financial supplements under Item 2.02.
The filings also record Genworth’s references to Enact Holdings as a publicly traded subsidiary, segment-level reporting context, conference-call notices and exhibit-based financial materials. These disclosures connect reported results to mortgage insurance performance, legacy insurance liabilities, investment impacts and holding-company capital actions.
GENWORTH FINANCIAL INC (GNW) President and CEO Thomas J. McInerney reported selling 100,000 shares of common stock on September 3, 2026 in an open-market transaction at a weighted average price of $10.526 per share, with individual trades ranging from $10.495 to $10.54 per share.
After this sale, he directly holds 5,068,883 shares of GNW common stock and indirectly holds 89,456 shares through trusts for children. No Rule 10b5-1 trading plan is reported for this transaction.
GENWORTH FINANCIAL INC (GNW) has a notice of proposed sale of restricted securities filed for the account of Thomas J. McInerney under Rule 144. The notice covers the potential sale of 100,000 shares of common stock, held at Fidelity Brokerage Services LLC, with an estimated aggregate market value of $1,052,594.71.
The shares to be sold were acquired from the issuer as compensation via restricted stock vesting on March 2, 2026. The issuer’s common stock is listed on the NYSE and identified with CUSIP 377851037. The Form 144 is signed by a duly authorized representative of Fidelity as attorney-in-fact for Thomas J. McInerney.
GENWORTH FINANCIAL INC (GNW) reported insider transactions by Melissa Hagerman, EVP and Chief HR Officer. On 2026-08-24 she sold 14,708 shares of Common Stock in a sale described as an open market or private transaction at $9.915 per share. On the same date she also disposed of 11,000 shares of Common Stock as a bona fide gift to a charitable organization at a reported price of $0.00 per share. The Rule 10b5-1 trading plan checkbox for this filing is not marked as being pursuant to such a plan.
GENWORTH FINANCIAL INC (GNW) insider Gregory S. Karawan, EVP and General Counsel, reported a sale of 40,000 shares of Common Stock on 2026-08-21 in a transaction classified as a sale in the open market or a private transaction. The shares were sold at a weighted average sales price of $9.9118 per share, based on a series of broker-assisted transactions with prices ranging from $9.89 to $9.925 per share, as disclosed in a footnote. After this transaction, Karawan directly held 343,121 shares of Genworth Financial common stock and indirectly held 4,723.871 shares through a 401(k) plan.
GENWORTH FINANCIAL INC (GNW) has a notice of proposed sale of securities filed under Rule 144 for the account of officer Melissa Hagerman. The filing covers up to 14,708 shares of common stock held at Fidelity Brokerage Services LLC, with an indicated transaction value of $145,829.82 and NYSE as the trading venue. The shares relate to restricted stock vesting dated February 16, 2026, with a stated proposed sale date of August 24, 2026. The notice is signed by a duly authorized representative of Fidelity as attorney-in-fact for Hagerman.
GENWORTH FINANCIAL INC (GNW) had an officer, Gregory S. Karawan, file a Rule 144 notice covering the planned sale of up to 40,000 shares of common stock through Fidelity Brokerage Services LLC. The shares, with an aggregate market value of $396,000.00, may be sold on or after 08/21/2026 and originate from restricted stock vesting compensation awards dated February 16, 2025, February 17, 2025, and March 3, 2025.
GENWORTH FINANCIAL, INC. (GNW) reported a leadership change. Thomas J. McInerney will return from a leave of absence and resume the role of President & Chief Executive Officer, and principal executive officer, effective September 2, 2026.
On that date, Jerome T. Upton will cease serving as Interim President and Chief Executive Officer (principal executive officer) and will continue in his existing role as Executive Vice President and Chief Financial Officer (principal financial officer).
Donald Smith & Co., Inc., together with DSCO Value Fund, L.P., reports beneficial ownership of 22,482,191 shares of Genworth Financial Inc. common stock, representing 5.87% of the class. Donald Smith & Co., Inc. has sole voting power over 21,777,866 shares and sole dispositive power over 22,245,006 shares, while DSCO Value Fund, L.P. has sole voting and dispositive power over 237,185 shares. The shares are held for advisory clients and fund investors, who retain the economic rights to dividends and sale proceeds, and to the reporter’s knowledge no single client holds more than five percent of the outstanding common stock.
Genworth Financial, Inc. reported for the quarter ended June 30, 2026 total revenues of $1,901 million, including premiums of $875 million and net investment income of $836 million. Net income available to common stockholders was $47 million, or $0.12 per diluted share. For the first six months of 2026, revenues were $3,678 million and net income available to common stockholders was $94 million, or $0.24 per diluted share.
Total assets were $87,363 million at June 30, 2026, with total investments of $58,973 million and Genworth stockholders’ equity of $8,728 million. Future policy benefits and policyholder account balances totaled $54,508 million and $13,895 million, respectively. Operating activities provided $143 million of net cash in the first half of 2026, while investing activities used $177 million.
Genworth continued capital management actions under its share repurchase authorization of up to $350 million. During the six months ended June 30, 2026, it repurchased 14,719,298 shares at an average price of $8.67 for a total cost of $129 million, contributing to 378,357,289 common shares outstanding at quarter-end. In July 2026, a further 514,057 shares were repurchased at an average price of $9.24, leaving approximately $128 million available under the program as of July 31, 2026.
Genworth Financial reported Q2 2026 net income available to common stockholders of $47 million, or $0.12 per diluted share. Adjusted operating income excluding the Closed Block, the company’s primary performance metric, was $112 million or $0.29 per diluted share. Results were led by majority-owned Enact, which generated $143 million of adjusted operating income, $15.2 billion of primary new insurance written, $274.0 billion of primary insurance in-force, and a 14% loss ratio. Enact’s estimated PMIERs sufficiency ratio was 161%, or $1,894 million above requirements, and it paid a quarterly dividend of $0.24 per share.
The Closed Block segment posted adjusted operating loss of $110 million, primarily from a $127 million pre-tax actual-versus-expected loss as long-term care claims rose and terminations stayed low. Legacy insurance companies’ statutory pre-tax income was $6 million, and the estimated consolidated RBC ratio was 286%, down from 289%. Holding-company cash and liquid assets were $215 million, including about $81 million held for future obligations. Genworth repurchased $62 million of shares in the quarter at an average price of $8.74, and $918 million cumulatively since program inception at an average of $6.47.